A phase I study of sequential vinorelbine followed by paclitaxel

被引:11
作者
Budman, DR
Weiselberg, L
O'Mara, V
Buchbinder, A
Lichtman, SM
Donahue, L
Adams, LM
机构
[1] NYU, Sch Med, N Shore Univ Hosp, Dept Med,Don Monti Div Oncol, Manhasset, NY 11030 USA
[2] Glaxo Wellcome Res & Dev Ltd, Clin Applicat Res, Res Triangle Pk, NC USA
关键词
breast cancer; paclitaxel; phase I; vinorelbine;
D O I
10.1023/A:1008351915582
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In vitro experiments suggest that administration of vinorelbine preceding paclitaxel results in synergistic cytotoxic effects. A phase I dose escalation trial of vinorelbine daily x 3 with paclitaxel on day 3 repeated every 28 days in metastatic breast cancer patients was completed. Patients and methods: Female patients, PS 0-2, without evidence of CNS disease or prior neuropathies were treated with vinorelbine at dose levels 7, 10, 13 mg/m(2) per day and paclitaxel over three hours at dose levels of 135, 175, and 200 mg/m(2). Results: Twenty-eight patients with six dose levels were studied. At dose level 1, patients developed intolerable but reversible neutropenia. Subsequent dose levels required filgrastim. Dose limiting toxicities were myalgia and fatigue at vinorelbine 13 mg/m(2) /day and paclitaxel 200 mg/m(2). Neuropathy was minor. Twelve of twenty-five patients with measurable disease had a rapid response which did not correlate with dose level. Conclusions: Sequential administration of these two agents demonstrates activity in breast cancer patients. Phase II dosing on this schedule should be vinorelbine 13 mg/m(2)/day x 3 and paclitaxel 175 mg/m(2). With proper selection of patients, concern about neurologic toxicity should not impede future trials of vinorelbine with paclitaxel.
引用
收藏
页码:861 / 863
页数:3
相关论文
共 12 条
[1]   Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer [J].
Acuña, LR ;
Langhi, M ;
Pérez, J ;
Acuña, JR ;
Machiavelli, M ;
Lacava, J ;
Vallejo, C ;
Romero, A ;
Fasce, H ;
Ortiz, E ;
Grasso, S ;
Amato, S ;
Rodríguez, R ;
Barbieri, M ;
Leone, B .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :74-81
[2]  
ADAMS DJ, 1994, P AM ASSOC CANC RES, V35, pA1944
[3]   Vinorelbine (Navelbine(R)): A third-generation vinca alkaloid [J].
Budman, DR .
CANCER INVESTIGATION, 1997, 15 (05) :475-490
[4]  
BUDMAN DR, 1996, P AM ASSOC CANC RES, V37, pA2493
[5]   Taxoids in combination chemotherapy for metastatic breast cancer [J].
Dieras, V ;
Fumoleau, P ;
Bourgeois, H ;
Misset, JL ;
Azli, N ;
Pouillart, P .
ANTI-CANCER DRUGS, 1996, 7 :47-52
[6]   Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death [J].
Dumontet, C ;
Sikic, BI .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :1061-1070
[7]   SOUTHWEST-ONCOLOGY-GROUP STANDARD RESPONSE CRITERIA, END-POINT DEFINITIONS AND TOXICITY CRITERIA [J].
GREEN, S ;
WEISS, GR .
INVESTIGATIONAL NEW DRUGS, 1992, 10 (04) :239-253
[8]  
HAVLIN K, 1996, P ANN M AM SOC CLIN, V15, pA154
[9]  
IBRAHIM N, 1995, P AM ASSOC CANC RES, V36, P1443
[10]  
Khayat D, 1995, P AN M AM SOC CLIN, V14, P469